The latest developments across the GLP-1 landscape, from new drug approvals and clinical research to pricing changes and policy shifts. Stay informed on the updates that affect Ozempic, Wegovy, Mounjaro, and the wider category.
News & Updates
A new blood test developed by Hepta Bio may be able to predict how well a patient will respond to GLP-1 medications before they ever take a dose. This could change how doctors prescribe semaglutide and tirzepatide, and potentially save patients significant time and money. Here's what you need to know.
Wegovy sales are breaking records and Novo Nordisk is reporting major profit highs driven by semaglutide demand. For patients already on GLP-1 medications or considering starting, surging sales have real implications for pricing, insurance coverage, and access. Here's what you need to know.
An oral version of semaglutide is drawing attention from patients who want the benefits of GLP-1 therapy without weekly injections. This guide breaks down how the Ozempic pill works, how it compares to the injectable, and what to consider before switching or starting.
Novo Nordisk has made oral versions of its semaglutide medications available through Amazon with same-day delivery in select areas. This shift could change how patients access GLP-1 therapy, but there are important details on cost, eligibility, and safety to understand before ordering.
Several states are revising their employee health benefit rules around GLP-1 medications like semaglutide and tirzepatide for weight loss. If you're a state employee or on a government health plan, these changes could affect your out-of-pocket costs and access. Here's what you need to know.
Amazon is expanding into GLP-1 medications by carrying oral semaglutide (the Ozempic pill) at U.S. pharmacy kiosks with same-day delivery. This shift could change how millions of Americans access weight and diabetes medications. Here's what you need to know before considering a switch.
A new NIH-funded study found that oral small-molecule GLP-1 drugs can penetrate deep into the brain's reward circuits, suppressing the urge to eat for pleasure in mice. This goes beyond appetite control and points to a fundamentally different way these medications may work. Here's what the research means if you're currently on or considering GLP-1 therapy.
Five new pharmaceutical companies are set to launch competing GLP-1 medications between late 2026 and 2027, with analysts projecting price drops of 40-60%. This means real choices are coming for patients who have been priced out of semaglutide and tirzepatide. Here's what to watch, what to ask your doctor, and how to prepare.
